Dr. Reddy's Laboratories (RDY) cash on hand
Dr. Reddy's Laboratories (RDY) held cash of ₹87.81B at the end of fiscal 2026 (March 31, 2026). That is 51.6% higher than the ₹57.91B of fiscal 2025. Figures as of 18 Nov 2026, 09:29 UTC, from Yahoo Finance.
Key facts
- Cash, fiscal 2026
- ₹87.81B
- Change on fiscal 2025
- +51.6%
- Highest on record
- ₹87.81Bfiscal 2026
- Lowest on record
- ₹57.91Bfiscal 2025
- Fiscal years on record
- 42023–2026
Figures as of . Statements from Yahoo Finance. Amounts are in INR. Figures, not advice.
Dr. Reddy's Laboratories cash on hand, in more detail
Across the 4 fiscal years on record (2023–2026), the highest was ₹87.81B in fiscal 2026 and the lowest ₹57.91B in fiscal 2025.
Cash by fiscal year
Dr. Reddy's Laboratories cash on hand, year by year
| Fiscal year | Cash | Change | Year ended |
|---|---|---|---|
| 2026 | ₹87.81B | 51.6% up | |
| 2025 | ₹57.91B | 28.9% down | |
| 2024 | ₹81.47B | 31.8% up | |
| 2023 | ₹61.80B | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Cash is the cash, cash equivalents and short-term investments on the balance sheet at the fiscal year-end, shown for the fiscal years the market data feed covers because the older SEC record counts cash and equivalents alone.
How to read it
Cash is the cushion that pays for bad years, buybacks and acquisitions; compare it with total debt to see whether the company is a net borrower.
Cash at health care companies of similar size
| Company | Cash | Fiscal year |
|---|---|---|
| Smith & Nephew SNN | $557.00M | 2025 |
| Dr. Reddy's Laboratories RDY | ₹87.81B | 2026 |
| Fresenius Medical Care FMS | €1.82B | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Dr. Reddy's Laboratories, figure by figure
- Dr. Reddy's Laboratories market cap
- Dr. Reddy's Laboratories revenue
- Dr. Reddy's Laboratories earnings
- Dr. Reddy's Laboratories earnings per share (EPS)
- Dr. Reddy's Laboratories P/E ratio
- Dr. Reddy's Laboratories P/S ratio
- Dr. Reddy's Laboratories P/B ratio
- Dr. Reddy's Laboratories free cash flow
- Dr. Reddy's Laboratories operating margin
- Dr. Reddy's Laboratories dividend
- Dr. Reddy's Laboratories shares outstanding
- Dr. Reddy's Laboratories total debt
- Dr. Reddy's Laboratories total assets
- Dr. Reddy's Laboratories return on equity (ROE)
- Dr. Reddy's Laboratories return on invested capital (ROIC)
Dr. Reddy's Laboratories (RDY) overview: price, valuation and scorecardAll health care companies by market value
Dr. Reddy's Laboratories cash on hand: questions and answers
How much cash does Dr. Reddy's Laboratories have?
Dr. Reddy's Laboratories (RDY) held cash of ₹87.81B at the end of fiscal 2026 (March 31, 2026). That is 51.6% higher than the ₹57.91B of fiscal 2025.
What are the highest and lowest cash figures on record for Dr. Reddy's Laboratories?
Across the 4 fiscal years on record (2023–2026), the highest was ₹87.81B in fiscal 2026 and the lowest ₹57.91B in fiscal 2025.
How is Dr. Reddy's Laboratories's cash calculated?
Cash is the cash, cash equivalents and short-term investments on the balance sheet at the fiscal year-end, shown for the fiscal years the market data feed covers because the older SEC record counts cash and equivalents alone. For Dr. Reddy's Laboratories it is on record here for 4 fiscal years, 2023 to 2026.
Fiscal years are named for the calendar year they end in.
Learn: cash on hand
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Dr. Reddy's Laboratories (RDY) cash on hand”, data as of 18 November 2026. https://funkfolio.com/stock/RDY/cash
Underlying data: Yahoo Finance.